We Think Shandong Boan Biotechnology (HKG:6955) Is Taking Some Risk With Its Debt
May 23
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedMay 27, 2025
DataAggregated Company Financials
Companies52
- 7D4.8%
- 3M35.5%
- 1Y69.2%
- YTDn/a
In the last week, the Biotech industry is up 4.8%, with 3SBio up 30%. This takes the industry's 12 month performance to a gain of 69%. Looking forward, earnings are forecast to grow by 43% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 27 May 2025 | HK$598.2b | HK$62.1b | -HK$11,738,301,850.31 | 31.1x | -51x | 9.6x |
| Thu, 24 Apr 2025 | HK$569.3b | HK$60.3b | -HK$12,141,257,693.36 | 30.7x | -46.9x | 9.4x |
| Sat, 22 Mar 2025 | HK$464.4b | HK$52.9b | -HK$16,899,036,991.92 | 22.3x | -27.5x | 8.8x |
| Mon, 17 Feb 2025 | HK$383.0b | HK$52.2b | -HK$17,364,199,594.37 | 14.2x | -22.1x | 7.3x |
| Wed, 15 Jan 2025 | HK$353.1b | HK$51.7b | -HK$16,886,791,563.70 | 12.2x | -20.9x | 6.8x |
| Fri, 13 Dec 2024 | HK$405.5b | HK$52.1b | -HK$17,317,776,756.08 | 11.3x | -23.4x | 7.8x |
| Sun, 10 Nov 2024 | HK$403.2b | HK$52.5b | -HK$17,637,137,036.48 | 11.6x | -22.9x | 7.7x |
| Tue, 08 Oct 2024 | HK$445.4b | HK$52.9b | -HK$18,143,085,062.73 | 13.1x | -24.5x | 8.4x |
| Thu, 05 Sep 2024 | HK$338.8b | HK$52.5b | -HK$19,512,112,816.92 | 11.2x | -17.4x | 6.5x |
| Sat, 03 Aug 2024 | HK$321.6b | HK$50.0b | -HK$19,621,133,103.77 | 11.6x | -16.4x | 6.4x |
| Mon, 01 Jul 2024 | HK$327.6b | HK$49.6b | -HK$19,441,769,600.62 | 12.1x | -16.9x | 6.6x |
| Wed, 29 May 2024 | HK$338.7b | HK$49.8b | -HK$19,505,887,561.30 | 11.3x | -17.4x | 6.8x |
| Fri, 26 Apr 2024 | HK$346.9b | HK$49.5b | -HK$19,469,847,113.03 | 11.8x | -17.8x | 7x |
| Sun, 24 Mar 2024 | HK$345.6b | HK$49.7b | -HK$19,699,938,439.12 | 14.1x | -17.5x | 7x |
| Tue, 20 Feb 2024 | HK$329.9b | HK$46.8b | -HK$20,168,860,809.96 | 16.4x | -16.4x | 7.1x |
| Thu, 18 Jan 2024 | HK$354.3b | HK$46.8b | -HK$20,184,432,385.00 | 17x | -17.6x | 7.6x |
| Sat, 16 Dec 2023 | HK$406.3b | HK$47.2b | -HK$20,376,104,618.00 | 17.9x | -19.9x | 8.6x |
| Mon, 13 Nov 2023 | HK$417.3b | HK$45.2b | -HK$18,924,858,618.00 | 13.5x | -22.1x | 9.2x |
| Wed, 11 Oct 2023 | HK$380.4b | HK$44.9b | -HK$19,115,913,057.00 | 13.3x | -19.9x | 8.5x |
| Fri, 08 Sep 2023 | HK$400.2b | HK$44.9b | -HK$18,889,389,617.00 | 15.3x | -21.2x | 8.9x |
| Sun, 06 Aug 2023 | HK$398.2b | HK$35.6b | -HK$23,393,254,800.00 | 22.3x | -17x | 11.2x |
| Tue, 04 Jul 2023 | HK$392.4b | HK$35.3b | -HK$23,202,884,962.00 | 25.7x | -16.9x | 11.1x |
| Thu, 01 Jun 2023 | HK$412.8b | HK$35.9b | -HK$23,645,687,154.00 | 26.8x | -17.5x | 11.5x |
| Sat, 29 Apr 2023 | HK$445.1b | HK$36.9b | -HK$23,365,935,236.00 | 17.8x | -19.1x | 12.1x |
| Mon, 27 Mar 2023 | HK$430.5b | HK$35.1b | -HK$35,058,747,287.00 | 22.5x | -12.3x | 12.3x |
| Wed, 22 Feb 2023 | HK$417.7b | HK$34.5b | -HK$34,860,112,837.00 | 33.1x | -12x | 12.1x |
| Fri, 20 Jan 2023 | HK$449.5b | HK$34.9b | -HK$35,241,637,476.00 | 29.4x | -12.8x | 12.9x |
| Sun, 18 Dec 2022 | HK$394.6b | HK$33.6b | -HK$33,868,975,451.00 | 24.3x | -11.7x | 11.8x |
| Tue, 15 Nov 2022 | HK$375.3b | HK$33.2b | -HK$33,509,711,772.00 | 17.2x | -11.2x | 11.3x |
| Thu, 13 Oct 2022 | HK$274.0b | HK$33.8b | -HK$32,318,825,304.00 | 15.6x | -8.5x | 8.1x |
| Sat, 10 Sep 2022 | HK$355.8b | HK$34.3b | -HK$33,625,291,716.00 | 17x | -10.6x | 10.4x |
| Mon, 08 Aug 2022 | HK$337.2b | HK$32.8b | -HK$46,282,522,083.00 | 12.1x | -7.3x | 10.3x |
| Wed, 06 Jul 2022 | HK$382.7b | HK$33.1b | -HK$46,626,033,002.00 | 15.1x | -8.2x | 11.6x |
| Fri, 03 Jun 2022 | HK$323.7b | HK$34.2b | -HK$46,119,353,466.00 | 13.1x | -7x | 9.5x |
Price to Earnings Ratio
-7x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | 0.81% | |
| Healthcare | 3.43% | |
| Biotech | 4.77% | |
| Biotech | 4.77% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$59.55 | 7.7% +HK$7.0b | 61.8% | PS9.6x | |
| 1877 Shanghai Junshi Biosciences | HK$17.86 | 13.9% +HK$2.1b | 57.5% | PS7.8x | |
| 6855 Ascentage Pharma Group International | HK$48.80 | 10.3% +HK$1.6b | 168.1% | PS15.7x | |
| 1541 ImmuneOnco Biopharmaceuticals (Shanghai) | HK$10.60 | 41.1% +HK$1.3b | -27.2% | PS49.8x | |
| 9926 Akeso | HK$83.80 | 1.7% +HK$1.3b | 144.3% | PS32.5x |
